Accuray Inc
NASDAQ:ARAY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Accuray Inc
Accuray, Inc. is a radiation oncology company. The company is headquartered in Sunnyvale, California and currently employs 995 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The firm's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Accuray, Inc. is a radiation oncology company. The company is headquartered in Sunnyvale, California and currently employs 995 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The firm's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Revenue Decline: Accuray reported Q1 revenue of $94 million, down 7% year-over-year and below expectations, mainly due to softer product sales in EIMEA and China.
Margin Pressure: Gross margin fell to 28.3% from 33.9% last year, driven by unfavorable sales mix, tariffs, and inventory charges; product gross margin was especially impacted.
Service Growth: Service revenue was a bright spot at $57 million, up 7% year-over-year, reflecting successful pricing actions and installed base expansion.
Transformation Plan: New CEO is prioritizing a transformation initiative targeting margin expansion, operational improvement, and sustainable growth, with more details coming early 2026.
Guidance Unchanged: Despite the slow start, full-year revenue guidance of $471–$485 million and adjusted EBITDA of $31–$35 million was reiterated.
Second Half Weighted: Management expects revenue and margins to improve in the second half of the fiscal year, with about 60% of revenue projected to be recognized then.
